Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 107

Results For "risk"

1506 News Found

Glenmark launches Sitagliptin and its FDC at affordable price
News | July 08, 2022

Glenmark launches Sitagliptin and its FDC at affordable price

These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens


Apollo Hospitals Navi Mumbai performs first minimally invasive mitral heart valve replacement
Healthcare | July 05, 2022

Apollo Hospitals Navi Mumbai performs first minimally invasive mitral heart valve replacement

Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery


50% of heart attacks now happens in Indians below 50 years: says Expert
Public Health | July 05, 2022

50% of heart attacks now happens in Indians below 50 years: says Expert

Younger Indians have a 10 times higher rate of heart attack


Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
Healthcare | July 05, 2022

Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Medicines, including insulin, to be available in 40 lower-income countries


Sanofi flu vaccines licensed and approved for 2022-2023 influenza season
Drug Approval | July 05, 2022

Sanofi flu vaccines licensed and approved for 2022-2023 influenza season

Sanofi will begin to ship their vaccines helping to ensure more people will be immunized


Pfizer submits new drug application to the U.S. FDA for Paxlovid
Drug Approval | July 03, 2022

Pfizer submits new drug application to the U.S. FDA for Paxlovid

Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk


Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
News | June 29, 2022

Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3

Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study


Medidata launches new clinical operations technologies to address clinical trial oversight issues
Digitisation | June 28, 2022

Medidata launches new clinical operations technologies to address clinical trial oversight issues

Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies


Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer
Drug Approval | June 28, 2022

Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival in patients


50%+ patients delay cataract surgeries in India: Survey
Public Health | June 28, 2022

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries